Chemomab Therapeutics Ltd

CMMB

2.650USD

-0.020-0.75%

Market hours （ET）Quotes delayed by 15 min

Chemomab Therapeutics Ltd's Score

Industry at a Glance

Industry Ranking

235 / 501

Overall Ranking

419 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

26.500

Target Price

+846.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Chemomab Therapeutics Ltd Highlights

StrengthsRisks

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Overvalued

The company’s latest PE is -1.57, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.06M shares, increasing 8.03% quarter-over-quarter.

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 7.34, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -1.57, which is -9.96% below the recent high of -1.42 and -359.02% above the recent low of -7.22.

Score

Industry at a Glance

Previous score

7.34

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 235/501

No Data

The company’s current earnings forecast score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Chemomab Therapeutics Ltd is 26.50, with a high of 28.00 and a low of 25.00.

Score

Industry at a Glance

Previous score

9.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 7.28, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 3.55 and the support level at 2.57, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.72

Change

-1.44

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Otto (Erik)

422.50K

+46.32%

Morgan Stanley & Co. LLC

403.53K

+1277.72%

Apeiron Investment Group Ltd

283.00K

+55.68%

Rivendell Investments 2017-9 LLC

277.13K

--

OrbiMed Advisors, LLC

235.25K

-45.96%

Sphera Funds Management Ltd.

184.51K

-18.03%

Mor George (Adi)

79.27K

--

Ikarian Capital LLC

53.26K

--

George (Kobi)

50.06K

-20.27%

Cohen (Neil Harris)

35.30K

-6.61%



1

2



There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.62. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Chemomab Therapeutics Ltd

CMMB

4.66 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

CytomX Therapeutics Inc

CTMX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Amicus Therapeutics Inc

FOLD

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.36 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment